A nationwide class of purchasers alleged that SmithKline Beecham promoted Paxil and Paxil CR for prescription to children and adolescents, despite actual knowledge that these drugs exposed them to dangerous side effects while also failing to treat their symptoms. The settlement established a $63.8 million fund to reimburse class members 100% of their out-of-pocket expenses.
The New York Attorney General’s Office settled its lawsuit concerning the same conduct for a $2.5 million fine.